Oncolytics Biotech (ONCY) shares rose 8% after its drug, pelareorep, received its second FDA Fast Track Designation. This one targets metastatic colorectal cancer, supported by data showing a 33% response rate. The drug already holds Fast Track status for pancreatic cancer, potentially speeding up the path to market for two major gastrointestinal diseases.